Moleculin Biotech, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MBRX in the last 30 days.
See all $MBRX insider activity →Moleculin Biotech (MBRX) completed Part A enrollment in its Phase 2/3 MIRACLE trial for relapsed AML, with 89 participants. The trial evaluates Annamycin plus cytarabine. Results are expected in Q1 2027. No cardiotoxicity observed. MBRX stock is currently at $0.56.
Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto
Moleculin Biotech (MBRX) published cardiac safety findings for Annamycin, showing no evidence of cardiotoxicity in 90 patients across five trials. Mean LVEF remained stable, and no relationship was found between cumulative Annamycin exposure and LVEF changes. The analysis supports continued clinical evaluation of Annamycin, which is being studied in the MIRACLE trial for relapsed or refractory AML. MBRX stock closed at $0.60, up 6.12%, and is currently down 1.26% in pre-market trading.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning MBRX (Moleculin Biotech, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent MBRX coverage spans technology, financial news and corporate actions.
Enrollment completion removes a near‑term uncertainty and sets the stage for upcoming Part A data, which could move the stock.
Enrollment completion signals strong execution and keeps the program on schedule for a Q1‑2027 data readout.
Positive safety data may lift investor confidence and support upcoming Phase 2/3 trial progress.
Positive safety data may reduce perceived risk and support further development, likely lifting the stock.
Positive preclinical immune‑mediated data may broaden Annamycin's potential indications and support future combination strategies.
AlphAI scores every news story that mentions MBRX with an AI model for sentiment and relevance, and aggregates insider trades from Moleculin Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Moleculin Biotech (MBRX) completed Part A enrollment in its Phase 2/3 MIRACLE trial for relapsed AML, with 89 participants. The trial evaluates Annamycin plus cytarabine. Results are expected in Q1 2027. No cardiotoxicity observed. MBRX stock is currently at $0.56.
2 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto
2 min readMoleculin Biotech (MBRX) published cardiac safety findings for Annamycin, showing no evidence of cardiotoxicity in 90 patients across five trials. Mean LVEF remained stable, and no relationship was found between cumulative Annamycin exposure and LVEF changes. The analysis supports continued clinical evaluation of Annamycin, which is being studied in the MIRACLE trial for relapsed or refractory AML. MBRX stock closed at $0.60, up 6.12%, and is currently down 1.26% in pre-market trading.
2 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine – Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding tradition
2 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Annamycin Turns “ Cold ” Pancreatic Tumors “ Hot ” in New Preclinical Data Presented at AACR Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin ’ s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-medi
1 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commerci
2 min readMoleculin Biotech (MBRX) shares dropped 25% after interim trial data for Annamycin in AML patients showed no statistical significance, though remission rates were higher than standard chemotherapy. The MIRACLE trial continues with 67 of 90 patients enrolled. The company has $10.317M in cash, expected to last until Q3 2026. CEO Klemp called results encouraging but noted more data is needed.
2 min readWalter V. Klemp, CEO of Moleculin Biotech (MBRX), disclosed a 9.87% stake in the company's common stock via a Schedule 13D filing on Aug. 25, 2026. He acquired shares and warrants in an Aug. 3, 2026 public offering and has the option to increase his ownership to 9.99%. Klemp may adjust his position and consider strategic transactions in the future.
2 min readMoleculin Biotech (MBRX) CFO Jonathan Foster invested $220K in the company's stock and warrants, acquiring 293,333 shares and warrants for 879,999 more. The purchase was part of a public offering, with funds from personal savings. Foster may increase his stake or change investment plans. He also participated in preparing proposals for the 2026 annual meeting, including a reverse stock split.
2 min readMoleculin Biotech (MBRX) CEO Walter Klemp invested $400K in the company's public offering, purchasing 533,333 shares and warrants for 1.6M more shares at $0.75 each. AnnaMed, a holding company, also owns 636 shares. Klemp plans to invest further, reserving the right to acquire or dispose of more securities.
1 min read
